Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Refametinib

Next Previous
X
Search
Drug Profile

Refametinib

Alternative Names: AR-119; BAY-86-9766; RDEA-119; VRX-119

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Valeant Pharmaceuticals International
  • Developer Ardea Biosciences; Bayer HealthCare; Samsung Medical Center
  • Class Aniline compounds; Anti-inflammatories; Antineoplastics; Small molecules; Sulfonamides
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer
  • Phase I/II Pancreatic cancer; Solid tumours
  • Discontinued Biliary cancer; Inflammation

Most Recent Events

  • 28 Dec 2022 Discontinued - Phase-II for Liver cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Metastatic disease) in Thailand, Turkey, Taiwan, Switzerland, United Kingdom, New Zealand, Singapore, Japan, Spain, South Korea, China, Belgium, Austria, Czech Republic, France, Germany, Italy, Israel, Hungary, Hong Kong, USA (PO, Capsule)
  • 28 Dec 2022 Discontinued - Phase-II for Liver cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Metastatic disease) in Thailand, Turkey, Taiwan, Switzerland, United Kingdom, New Zealand, Singapore, Japan, Spain, South Korea, China, Belgium, Austria, Czech Republic, France, Germany, Italy, Israel, Hungary, Hong Kong, USA (PO, Tablet)
  • 04 Feb 2020 Discontinued - Phase-II for Biliary cancer (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in South Korea (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top